Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03618550 |
Title | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Memorial Sloan Kettering Cancer Center |
Indications | |
Therapies | |
Age Groups: | child | senior | adult |
Covered Countries | USA |